Semaglutide is a leading GLP-1 (Glucagon-Like Peptide-1) receptor agonist that represents a significant advancement in the management of weight and type 2 diabetes. It works by emulating the body's natural incretin hormones, which play a crucial role in appetite regulation, slowing stomach emptying, and enhancing the body's insulin response to meals. This multifaceted action leads to reduced caloric intake, better glycemic control, and often, substantial weight loss. At Genesis Health Solutions, Semaglutide treatment is always personalized to your unique health profile and specific goals, forming part of a holistic wellness strategy.

Semaglutide exerts its effects by selectively binding to and activating GLP-1 receptors located in various tissues, most notably the pancreas and the brain. In the pancreas, it stimulates the release of insulin and suppresses the secretion of glucagon (a hormone that raises blood sugar) in a glucose-dependent manner, which helps to lower overall blood sugar when levels are elevated. In the brain, it interacts with areas responsible for appetite control, leading to increased feelings of fullness (satiety) and a decrease in hunger signals. It also slows down the rate at which food leaves the stomach, further contributing to satiety and reducing food consumption.

Semaglutide is typically administered via subcutaneous (under the skin) injection once weekly, or as a once-daily oral tablet. Dosage usually starts low and is gradually increased under medical supervision to optimize efficacy and minimize side effects; adherence to the prescribed dosing schedule and administration technique is critical. Gastrointestinal side effects are the most common, particularly when initiating therapy or increasing doses, and may include nausea, vomiting, diarrhea, constipation, or abdominal discomfort, though these effects often lessen over time as the body adjusts. A thorough medical history is essential before starting Semaglutide, and you should inform your Genesis Health Solutions provider of all medical conditions, especially any history of pancreatitis, medullary thyroid carcinoma (or a family history of it), multiple endocrine neoplasia syndrome type 2 (MEN 2), diabetic retinopathy, or significant kidney disease, as Semaglutide is not suitable for all individuals. Regular follow-up appointments are crucial to monitor treatment progress, manage any side effects, assess overall health, and make any necessary adjustments to the treatment plan.